| 초록 |
Silica nanoparticle has attracted great interest in drug delivery system. The advantage of silica-based nanoparticle is high drug loading due to its large surface area. However, biocompatibility of silica nanoparticle has been issued. Siloxane bonding can be hydrolyzed naturally in the body fluid but its rate is slow and potential accumulation of nanoparticle can be harmful to body. Including biocompatibility, there are some prerequisites for drug delivery system, such as stable encapsulation and tumor targeting. Herein, we report MMP-responsive biodegradable silica nanoparticle for tumor treatment. Silica nanoparticle can be vulnerable to reductive condition by putting disulfide bond between the bond that constitutes the framework of silica nanoparticle. In addition, capping the surface of nanoparticle with polymer can prevent the premature release of drugs. Introduction of peptide crosslinker PLGVR cleaved by MMP-2 enzyme makes nanoparticle sensitive to tumor microenvironment. |
